PTC Therapeutics, Inc. Concurrent $100 Million Common Stock Offering and $287.5 Million Convertible Senior Notes Offering

Davis Polk advised the underwriter in connection with the SEC-registered offering by PTC Therapeutics, Inc. of 2,475,248 shares of its common stock and the initial purchaser in a concurrent Rule 144A offering by PTC Therapeutics, Inc. of $287.5 million aggregate principal amount of its 1.50% convertible senior notes due 2026, including $37.5 million aggregate principal amount of convertible notes pursuant to the exercise of the initial purchaser’s option to purchase additional convertible notes. The common stock is listed on the Nasdaq Global Select Market under the symbol “PTCT.”

Based in Plainfield, New Jersey, PTC Therapeutics is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders.

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Yasin Keshvargar and associates Carrie Guo and David Li. The equity derivatives team included partner Ray Ibrahim and associate Justin Lashley. The intellectual property and technology team included partner Pritesh P. Shah and associate Yifu Chen. The tax team included partner Lucy W. Farr and associate Joseph M. Gerstel. All members of the Davis Polk team are based in the New York office.